NCT03391973
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03391973
Title Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP)
Acronym CUP
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors AHS Cancer Control Alberta
Indications
Therapies
Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.